Patents by Inventor Alessandro Accetta
Alessandro Accetta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240092790Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are dihydrofuropyridine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).Type: ApplicationFiled: December 13, 2021Publication date: March 21, 2024Applicant: CHIESI FARMACEUTICI S.P.A.Inventors: Fabio RANCATI, Alessandro ACCETTA, Anna Maria CAPELLI, Daniele PALA, Christine EDWARDS, Adele Elisa PASQUA, Prashant Bhimrao KAPADNIS, Arnaud Jean Francois Auguste CHEGUILLAUME, David Edward CLARK
-
Publication number: 20240092791Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are dihydrofuropyridine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).Type: ApplicationFiled: December 13, 2021Publication date: March 21, 2024Applicant: CHIESI FARMACEUTICI S.P.A.Inventors: Fabio RANCATI, Alessandro ACCETTA, Anna Maria CAPELLI, Daniele PALA, Christine EDWARDS, Adele Elisa PASQUA, Prashant Bhimrao KAPADNIS, Arnaud Jean Francois Auguste CHEGUILLAUME, David Edward CLARK
-
Publication number: 20240092792Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are dihydrofuropyridine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).Type: ApplicationFiled: December 13, 2021Publication date: March 21, 2024Applicant: CHIESI FARMACEUTICI S.P.A.Inventors: Fabio RANCATI, Alessandro ACCETTA, Anna Maria CAPELLI, Daniele PALA, Christine EDWARDS, Adele Elisa PASQUA, Prashant Bhimrao KAPADNIS, Arnaud Jean Francois Auguste CHEGUILLAUME
-
Publication number: 20240082223Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are dihydrofuropyridine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).Type: ApplicationFiled: December 13, 2021Publication date: March 14, 2024Applicant: CHIESI FARMACEUTICI S.P.A.Inventors: Fabio RANCATI, Alessandro ACCETTA, Anna Maria CAPELLI, Daniele PALA, Roberta MAZZUCATO, Christine EDWARDS, Adele Elisa PASQUA
-
Patent number: 11725007Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are meta tyrosine derivatives, processes for preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).Type: GrantFiled: December 12, 2018Date of Patent: August 15, 2023Assignee: Chiesi Farmaceutici S.p.A.Inventors: Alessandro Accetta, Fabio Rancati, Christine Edwards, Gurdip Bhalay, Patrizia Tisselli
-
Patent number: 11578068Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are oxidazole derivatives, processes for preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).Type: GrantFiled: December 12, 2018Date of Patent: February 14, 2023Assignee: Chiesi Farmaceutici S.p.A.Inventors: Alessandro Accetta, Fabio Rancati, Christine Edwards, Elizabeth Anne Skidmore
-
Patent number: 11332468Abstract: The invention relates to compounds of formula I inhibiting Rho Kinase that are tyrosine analogues derivatives, processes of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).Type: GrantFiled: December 14, 2018Date of Patent: May 17, 2022Assignee: CHIESI FARMACEUTICI S.P.A.Inventors: Alessandro Accetta, Fabio Rancati, Christine Edwards, Andrea Nuzzi
-
Patent number: 11147812Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are tyrosine analogues derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).Type: GrantFiled: September 5, 2018Date of Patent: October 19, 2021Assignee: Chiesi Farmaceutici S.p.A.Inventors: Alessandro Accetta, Anna Maria Capelli, Fabio Rancati, Gurdip Bhalay, Arnaud Jean Francois Auguste Cheguillaume, Christine Edwards, Patrizia Tisselli
-
Publication number: 20210284639Abstract: The invention relates to compounds of formula I inhibiting Rho Kinase that are bicyclic dihydropyrimidine-carboxamide derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).Type: ApplicationFiled: July 12, 2019Publication date: September 16, 2021Applicant: CHIESI FARMACEUTICI S.p.A.Inventors: Alessandro ACCETTA, Fabio RANCATI, Anna Maria CAPELLI, David Edward CLARK, Patrizia TISSELLI, Christine EDWARDS, Amaud Jean Francois Auguste CHEGUILLAUME, Gurdip BHALAY
-
Publication number: 20210253568Abstract: The invention relates to compounds of formula I inhibiting Rho Kinase that are azaindole derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).Type: ApplicationFiled: June 11, 2019Publication date: August 19, 2021Applicant: CHIESI FARMACEUTICI S.p.A.Inventors: Alessandro ACCETTA, Fabio RANCATI, David Edward CLARK, Christine EDWARDS
-
Patent number: 10954236Abstract: Bicyclic dihydropyrimidine-carboxamide compounds of formula I described herein inhibit Rho Kinase and may be used for the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).Type: GrantFiled: October 18, 2019Date of Patent: March 23, 2021Assignee: CHIESI FARMACEUTICI S.P.A.Inventors: Alessandro Accetta, Fabio Rancati, Anna Maria Capelli, David Edward Clark, Patrizia Tisselli, Christine Edwards, Gurdip Bhalay, Arnaud Jean Francois Auguste Cheguillaume
-
Publication number: 20210023080Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are tyrosine analogues derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).Type: ApplicationFiled: September 5, 2018Publication date: January 28, 2021Inventors: Alessandro ACCETTA, Anna Maria CAPELLI, Fabio RANCATI, Gurdip BHALAY, Arnaud Jean Francois Auguste CHEGUILLAUME, Christine EDWARDS, Patrizia TISSELLI
-
Publication number: 20200392133Abstract: The invention relates to compounds of formula I inhibiting Rho Kinase that are tyrosine analogues derivatives, processes of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).Type: ApplicationFiled: December 14, 2018Publication date: December 17, 2020Inventors: Alessandro ACCETTA, Fabio RANCATI, Christine EDWARDS, Andrea NUZZI
-
Publication number: 20200377500Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are meta tyrosine derivatives, processes for preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).Type: ApplicationFiled: December 12, 2018Publication date: December 3, 2020Inventors: Alessandro ACCETTA, Fabio RANCATI, Christine EDWARDS, Gurdip BHALAY, Patrizia TISSELLI
-
Publication number: 20200331912Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are oxidazole derivatives, processes for preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).Type: ApplicationFiled: December 12, 2018Publication date: October 22, 2020Inventors: Alessandro ACCETTA, Fabio RANCATI, Christine EDWARDS, Elizabeth Anne SKIDMORE
-
Publication number: 20200079774Abstract: Bicyclic dihydropyrimidine-carboxamide compounds of formula I described herein inhibit Rho Kinase and may be used for the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).Type: ApplicationFiled: October 18, 2019Publication date: March 12, 2020Applicant: CHIESI FARMACEUTICI S.P.A.Inventors: Alessandro ACCETTA, Fabio RANCATI, Anna Maria CAPELLI, David Edward CLARK, Patrizia TISSELLI, Christine EDWARDS, Gurdip BHALAY, Arnaud Jean Francois Auquste CHEGUILLAUME
-
Patent number: 10584128Abstract: Bicyclic dihydropyrimidine-carboxamide compounds of formula I described herein inhibit Rho Kinase and may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and pulmonary arterial hypertension (PAH).Type: GrantFiled: December 21, 2017Date of Patent: March 10, 2020Assignee: CHIESI FARMACEUTICI S.p.A.Inventors: Alessandro Accetta, Fabio Rancati, Anna Maria Capelli, David Edward Clark, Patrizia Tisselli, Christine Edwards, Gurdip Bhalay
-
Patent number: 10501461Abstract: Tyrosine amide compounds of formula I described herein inhibit Rho Kinase and may be used for the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).Type: GrantFiled: January 30, 2018Date of Patent: December 10, 2019Assignee: CHIESI FARMACEUTICI S.P.A.Inventors: Alessandro Accetta, Fabio Rancati, Anna Maria Capelli, David Edward Clark, Patrizia Tisselli, Christine Edwards, Gurdip Bhalay, Arnaud Jean Francois Auguste Cheguillaume
-
Publication number: 20180215758Abstract: Bicyclic dihydropyrimidine-carboxamide compounds of formula I described herein inhibit Rho Kinase and may be used for the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).Type: ApplicationFiled: January 30, 2018Publication date: August 2, 2018Applicant: CHIESI FARMACEUTICI S.P.A.Inventors: Alessandro Accetta, Fabio Rancati, Anna Maria Capelli, David Edward Clark, Patrizia Tisselli, Christine Edwards, Gurdip Bhalay, Arnaud Jean Francois Auguste Cheguillaume
-
Publication number: 20180170939Abstract: Bicyclic dihydropyrimidine-carboxamide compounds of formula I described herein inhibit Rho Kinase and may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and pulmonary arterial hypertension (PAH).Type: ApplicationFiled: December 21, 2017Publication date: June 21, 2018Applicant: CHIESI FARMACEUTISI S.p.A.Inventors: Alessandro Accetta, Fabio Rancati, Anna Maria Capelli, David Edward Clark, Patrizia Tisselli, Christine Edwards, Gurdip Bhalay